Developing small molecule therapeutics for TDP-43 associated neurodegenerative diseases - last updated: 01/29/2025 07:01:36 PM project summary neurodegenerative diseases, including amyotrophic lateral…
Active Grant Awarded
- Award ID
- R56AG097418
- Recipient
-
University Of Arizona UEI ED44Y3W6P7B9 Part of Arizona Board Of Regents
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $639,943
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 21% complete
- Place of performance
- Arizona, USA
Award details come from USAspending.gov.
About this award
The HHS National Institutes of Health's National Institute on Aging awarded Grant R56AG097418 to the University of Arizona, doing business as Arizona Board of Regents, with $639,943 obligated on September 9, 2026, under Assistance Listing 93.866, Aging Research. The grant funds development of small molecule therapeutics for TDP-43-associated neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and related dementias. The recipient will advance optimized derivatives of XL20, a small molecule that reduced TDP-43 aggregation and extended lifespan in transgenic mouse models in preclinical work. The project applies structure-based rational drug design and structure-activity relationship analyses to enhance potency, specificity, and drug-like properties. It then uses high-throughput in vitro screening to identify top candidates that bind effectively, suppress TDP-43 aggregation, and restore mitochondrial and neuronal function in primary neurons and iPSC-derived human motor neurons. Place of performance is Arizona, USA, and the ultimate completion date is August 31, 2027. The award is a grant. The Aging Research program supports biomedical, social, and behavioral research and training on the aging process, with the National Institute on Aging's mission emphasizing prevention and treatment of Alzheimer's disease and its related dementias.
Description
Developing small molecule therapeutics for TDP-43 associated neurodegenerative diseases - last updated: 01/29/2025 07:01:36 PM project summary neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), alzheimer's disease (ad), and related dementias such as limbic-predominant age-related TDP-43 encephalopathy (LATE) and cerebral age-related TDP-43 with sclerosis (CARTS), are characterized by progressive neuronal loss and the accumulation of pathological protein aggregates. Among these, TDP-43 proteinopathy has emerged as a central contributor to disease progression. This pathological feature involves the mislocalization of TDP-43 from the nucleus to the cytoplasm, leading to aggregation, mitochondrial dysfunction, and disruption of RNA metabolism. Despite its importance, no therapeutic strategies specifically targeting TDP-43 toxicity have reached clinical application. Our research has identified a promising small molecule, XL20, that addresses this critical need by targeting a key domain implicated in TDP-43'S pathological functions. XL20 demonstrated robust preclinical efficacy, reducing TDP-43 aggregation, improving mitochondrial bioenergetics, enhancing neuronal survival, and extending lifespan in transgenic mouse models of TDP-43 proteinopathy. These findings underscore its potential as a transformative therapeutic candidate. This project seeks to build on these promising findings by advancing the development of optimized XL20 derivatives by leveraging structure-based rational drug design to enhance their potency, specificity, and drug-like properties. Systematic modifications and structure-activity relationship analyses will guide the optimization process, followed by high-throughput in vitro screening to identify top candidates capable of binding effectively, suppressing TDP- 43 aggregation, and restoring mitochondrial and neuronal function in primary neurons and ipsc-derived human motor neurons. Comprehensive evaluations in disease mouse models will assess safety, pharmacokinetics, and pharmacodynamics, as well as their potential to mitigate TDP-43 neurotoxicity, improve mitochondrial health, and enhance motor and cognitive performance. The significance of this work lies in its focus on a central and underexplored pathological mechanism shared across multiple neurodegenerative diseases. Targeting TDP-43 likely offers a common therapeutic approach that could benefit patients with diverse disorders, including ALS, FTD, ad, and adrds. Moreover, this project is innovative in integrating state-of-the-art drug design with rigorous validation in preclinical models, bridging the GAP between discovery and translational application. By developing potent, selective, and pharmacologically relevant CR-targeting inhibitors, this work has the potential to transform treatment strategies for TDP-43-linked neurodegeneration, addressing a critical unmet need in the translational research of neurodegenerative diseases.
Quick answers
Who received award R56AG097418?
R56AG097418 was awarded to University Of Arizona by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R56AG097418 worth?
$639,943 has been obligated on R56AG097418.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award